Gail L. Brown

Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra®, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome

Azra Raza, Naomi Galili, Natalie S. Callander et al. · Journal of Hematology & Oncology · 2009 · 66 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome

Azra Raza, Naomi Galili, Scott E. Smith et al. · Blood · 2009 · 65 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Randomized Phase III Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin Compared With Pegylated Liposomal Doxorubicin Alone in Platinum-Resistant Ovarian Cancer

Ignace Vergote, Neil J. Finkler, James B. Hall et al. · International Journal of Gynecological Cancer · 2010 · 62 citations

Medicine, Oncology, Pharmacology +16

A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate‐1 risk myelodysplastic syndrome

Azra Raza, Naomi Galili, Scott E. Smith et al. · Cancer · 2011 · 44 citations · Full text

Medicine, Hematology, Pharmacology +16

Phase I study of TLK286 (glutathione S-transferase P1-1 activated glutathione analogue) in advanced refractory solid malignancies.

Lee S. Rosen, Joseph Brown, Bernadette Laxa et al. · PubMed · 2003 · 37 citations

Pharmacy, Oncology, Pharmacology +12